Acg Pharma Technologies Profile
Key Indicators
- Authorised Capital ₹ 126.20 Cr
as on 24-10-2024
- Paid Up Capital ₹ 122.29 Cr
as on 24-10-2024
- Company Age 28 Year, 3 Days
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.63 Cr
as on 24-10-2024
- Revenue -28.02%
(FY 2023)
- Profit -1145.41%
(FY 2023)
- Ebitda -1437.27%
(FY 2023)
- Net Worth -19.44%
(FY 2023)
- Total Assets -12.86%
(FY 2023)
About Acg Pharma Technologies
- CIN/LLPIN
U29251MH1996PTC104558
- Company No.
104558
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Dec 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Acg Pharma Technologies?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rashmi Mishra  | Company Secretary | 25-Jul-2019 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karan Singh  | Director | 01-Apr-2013 | Current |
| Jasjit Singh | Director | 17-Dec-1996 | Current |
| Ajit Singh | Director | 17-Dec-1996 | Current |
| Shaju Thommana | Whole-Time Director | 16-Oct-2019 | Current |
Financial Performance and Corporate Structure Insights of Acg Pharma Technologies.
Acg Pharma Technologies Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 28.02% decrease. The company also saw a substantial fall in profitability, with a 1145.41% decrease in profit. The company's net worth observed a substantial decline by a decrease of 19.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Acg Pharma Technologies?
In 2023, Acg Pharma Technologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Custom Capsules Private LimitedActive 36 years 2 monthsJasjit Singh and Ajit Singh are mutual person
Acg Associated Capsules Private LimitedActive 63 years 5 monthsKaran Singh, Jasjit Singh and 1 more are mutual person
- Acg Pam Pharma Technologies Private LimitedActive 52 years 9 months
Karan Singh, Jasjit Singh and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 09 Mar 2007 | ₹2.50 Cr | Satisfied |
State Bank Of India Creation Date: 14 Aug 2000 | ₹1.25 M | Satisfied |
How Many Employees Work at Acg Pharma Technologies?
Acg Pharma Technologies has a workforce of 348 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Acg Pharma Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Acg Pharma Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
